-
Infinity Media
- 11 Min Read
- 27 Views
Patrick Soon-Shiong: Biography, Net Worth And Business Career
Patrick Soon-Shiong’s life story is nothing short of remarkable—a journey that takes him from his early years in apartheid South Africa to becoming one of the world’s most influential figures in medicine, biotechnology, and media. Known for his groundbreaking work as a transplant surgeon and for inventing the revolutionary cancer drug Abraxane, Soon-Shiong has built a business empire that spans pharmaceuticals, healthcare technology, and even media. This blog post explores his biography, net worth, family life, and business career in a detailed yet accessible manner.
Early Life and Education
Born on July 29, 1952, in Port Elizabeth, South Africa, Patrick Soon-Shiong was raised in an environment marked by the challenges of apartheid. His parents, Chinese immigrants who fled turmoil in their homeland, instilled in him a strong sense of determination and resilience from an early age. Growing up in South Africa during turbulent times, Soon-Shiong learned early on about overcoming obstacles and the importance of hard work.
He displayed exceptional academic prowess and was admitted to the University of the Witwatersrand, where he earned his Bachelor of Medicine, Bachelor of Surgery (MBBCh). Graduating at a young age, Soon-Shiong ranked among the top students in his class—a precursor to his future achievements in medicine. He furthered his education by earning a Master of Science from the University of British Columbia, which broadened his perspective on scientific research and medical innovation. These formative experiences laid a robust foundation in both clinical practice and research, preparing him for a future where he would blend medicine with groundbreaking scientific advances.
Family and Personal Life
Family has always played a central role in Patrick Soon-Shiong’s life. He is married to Michele B. Chan, a former actress who has been both a partner and a strong pillar of support throughout his career. Together, they have two children, one of whom is Nika Soon-Shiong. Despite the pressures of building a vast business empire and the challenges inherent in the healthcare industry, Soon-Shiong has managed to maintain a balanced personal life. His family’s support and shared values have been instrumental in his journey, reminding him of the importance of staying grounded while pursuing extraordinary ambitions.
Growing up in a multicultural environment—South Africa’s diverse society during apartheid—the Soon-Shiong family learned early on about resilience, the importance of education, and the value of community support. These lessons have continued to guide Patrick both personally and professionally, influencing his approach to business, philanthropy, and even his investments in community projects.
Early Career in Medicine and Transplant Surgery
Soon-Shiong began his career as a practicing surgeon—a field that would become the launching pad for his future innovations. After completing his medical degree and surgical training, he joined UCLA Medical School in 1983. As a transplant surgeon, he quickly distinguished himself by performing pioneering procedures. Notably, he performed UCLA’s first whole-organ pancreas transplant and later became known for his work in islet cell transplantation—a technique aimed at treating diabetes by transplanting clusters of pancreatic cells.
His early surgical career was marked by a relentless pursuit of innovation. Soon-Shiong was not content to simply follow established protocols; he sought to improve them. His early experiments and clinical work set the stage for his later ventures into biotechnology, where he would combine his medical expertise with cutting-edge research to develop life-saving treatments.
Breakthrough: The Invention of Abraxane
One of Soon-Shiong’s most significant contributions to medicine is the invention of Abraxane. Developed in the mid-1990s, Abraxane is a nanoparticle albumin-bound formulation of paclitaxel—a chemotherapy drug used to treat various cancers including breast, lung, and pancreatic cancer. The drug works by exploiting the natural tendency of tumors to absorb albumin, a protein that the cancer cells use as a fuel source, thereby delivering the chemotherapeutic agent directly to the tumor.
Approved by the FDA in 2005, Abraxane quickly became a cornerstone in cancer treatment, generating annual global sales of around $1 billion. Its success not only improved survival rates for many cancer patients but also demonstrated the power of combining nanotechnology with traditional pharmaceuticals. The innovative nature of Abraxane earned it a place in the Smithsonian National Museum of American History, symbolizing its impact on both medicine and technology.
Building a Business Empire
APP Pharmaceuticals and Abraxis BioScience
Leveraging the success of Abraxane, Patrick Soon-Shiong ventured into the business side of medicine. In 1991, he founded VivoRx Inc., which later evolved into APP Pharmaceuticals. Under his leadership, APP Pharmaceuticals became a significant player in the pharmaceutical industry, producing essential drugs and medical products. In 2008, APP Pharmaceuticals was sold to Fresenius SE for approximately $4.6 billion—a deal that marked one of the early major financial milestones in Soon-Shiong’s career.
Building on this success, he went on to found Abraxis BioScience. Abraxis focused on developing innovative cancer treatments, with Abraxane being its flagship product. The company’s groundbreaking work and rapid growth culminated in its acquisition by Celgene in 2010 for over $3.8 billion. These two transactions not only cemented Soon-Shiong’s reputation as a visionary in pharmaceutical innovation but also provided the capital that would later fuel his next ventures.
The Rise of NantWorks and Healthcare Transformation
With billions in proceeds from his earlier deals, Soon-Shiong founded NantWorks in 2011—an umbrella organization designed to bring together a network of companies focused on transforming healthcare through the convergence of medicine, technology, and data science. NantWorks encompasses a variety of subsidiaries, each dedicated to different facets of healthcare innovation. Two of its notable companies include NantHealth, which leverages bioinformatics and deep learning to empower healthcare professionals with real-time data, and NantKwest, an immunotherapy company focusing on harnessing the power of Natural Killer cells to fight cancer.
Through NantWorks, Soon-Shiong has aimed to revolutionize the way healthcare is delivered, making it more personalized and efficient. By integrating cutting-edge technologies such as artificial intelligence, genomics, and advanced data analytics, his companies strive to break down traditional barriers in medicine and pave the way for next-generation treatments. This approach has redefined the landscape of healthcare innovation, positioning Soon-Shiong as a leader in the digital transformation of medicine.
Media and Other Ventures
Beyond the realms of healthcare and pharmaceuticals, Patrick Soon-Shiong has made a bold foray into the media industry. In 2018, he acquired the Los Angeles Times and the San Diego Union-Tribune for $500 million. This move signified his interest in reshaping journalism in the digital age. Under his ownership, the Los Angeles Times has undergone significant changes, including efforts to modernize its newsroom and expand its digital presence. Although his tenure has seen challenges—such as layoffs and editorial controversies—Soon-Shiong remains committed to supporting quality journalism, emphasizing the role of media as a pillar of democracy.
Additionally, Soon-Shiong is a minority owner of the Los Angeles Lakers, holding a 4.5% stake in the iconic NBA franchise. His involvement in sports further diversifies his portfolio and underscores his multifaceted approach to business. His investments in media and sports, alongside his healthcare ventures, illustrate a unique blend of interests that extend his influence well beyond the medical field.
Net Worth: A Billionaire’s Wealth
Patrick Soon-Shiong’s net worth is a subject of much fascination and fluctuates depending on market conditions and the valuation of his numerous holdings. According to Bloomberg Billionaires Index and Wikipedia, his net worth is currently estimated to be around US$11.2 billion as of 2025. However, other sources such as the Los Angeles Business Journal have reported figures as high as $19.8 billion or more in previous assessments. These variations reflect the dynamic nature of his investments in both public and private companies, including his stakes in NantWorks subsidiaries, the Los Angeles Times, and the Los Angeles Lakers.
Soon-Shiong’s wealth is not merely a number on a balance sheet—it is a testament to decades of relentless innovation, strategic acquisitions, and groundbreaking contributions to healthcare. His financial success has enabled him to reinvest in new ventures and support initiatives that aim to transform global health. Moreover, his wealth has afforded him the opportunity to become a leading philanthropist, supporting causes in education, health research, and community development.
While net worth estimates can vary, one thing is clear: Patrick Soon-Shiong’s journey from a talented young surgeon to one of the world’s richest and most influential businessmen exemplifies the power of vision combined with hard work and innovation.
Philanthropy and Legacy
Throughout his career, Patrick Soon-Shiong has demonstrated a deep commitment to giving back. His philanthropic endeavors are driven by a desire to improve healthcare accessibility and support scientific research across the globe. He chairs the Chan Soon-Shiong Family Foundation, which works to fund initiatives in health care and education. Additionally, he is the chairman of the Chan Soon-Shiong Institute for Advanced Health, an organization dedicated to advancing medical research and the dissemination of healthcare information.
Soon-Shiong’s contributions to philanthropy extend to his support for initiatives in Africa. Recognizing the urgent need for improved healthcare infrastructure on the continent, he has invested in projects aimed at vaccine manufacturing and disease prevention. His efforts in this area are a reflection of his belief that healthcare innovation should benefit people worldwide, not just those in wealthy nations.
In the realm of education and research, Soon-Shiong has supported numerous institutions and initiatives, ensuring that future generations of scientists and physicians have the resources they need to pursue innovative ideas. His legacy is not only defined by his financial success but also by his lasting impact on global health and his dedication to nurturing the next generation of medical innovators.
Overcoming Challenges and Controversies
Like many transformative leaders, Patrick Soon-Shiong’s career has not been without controversy. His ownership of the Los Angeles Times, for instance, has sparked debates over editorial independence and the challenges of running a legacy media institution in a rapidly changing digital landscape. Decisions made in the newsroom and controversies surrounding layoffs have drawn public criticism and sparked discussions about the future of journalism.
Despite these challenges, Soon-Shiong has remained steadfast in his vision. He often explains that his goal is to support quality journalism that upholds the values of a free press, even if the transition period is rocky. His approach to managing controversies reflects his broader philosophy: that long-term progress sometimes requires tough decisions and that the ultimate goal is to create sustainable, positive change.
In the healthcare industry, too, Soon-Shiong has faced skepticism and resistance—common hurdles when introducing disruptive innovations. However, his ability to persist through regulatory challenges, market fluctuations, and scientific uncertainties has been a key factor in his enduring success. His story is a powerful reminder that groundbreaking achievements often come with setbacks, and that resilience is crucial for anyone aiming to change the world.
The Future: Continuing to Shape Global Health
Patrick Soon-Shiong is not content to rest on his laurels. With NantWorks at the helm, he continues to drive innovation in healthcare, biotech, and artificial intelligence. His vision for the future includes the development of personalized medicine—where treatments are tailored to the genetic and molecular profiles of individual patients. This approach promises to revolutionize cancer treatment, improve outcomes, and reduce side effects by targeting therapies more precisely.
Soon-Shiong’s commitment to leveraging technology for better health outcomes is evident in his ongoing work with NantHealth and NantKwest. These companies are at the forefront of using big data, bioinformatics, and advanced imaging techniques to empower physicians with real-time information, thereby improving diagnostic accuracy and treatment efficacy. His focus on creating a seamless integration of technology and healthcare is transforming how patients access and receive care.
Moreover, his investments in global health initiatives, particularly in Africa, underscore his belief that healthcare innovation should be a global endeavor. By establishing partnerships and supporting infrastructure development, Soon-Shiong is helping to build a future where high-quality medical care is accessible to all, regardless of geography or economic status.
Conclusion
Patrick Soon-Shiong’s journey—from his early days as a top student in apartheid South Africa, to a pioneering transplant surgeon, to a billionaire entrepreneur and philanthropist—is a testament to the power of vision, resilience, and hard work. His achievements in medicine, particularly the invention of Abraxane, have saved countless lives and changed the course of cancer treatment. Through the founding and sale of major pharmaceutical companies like APP Pharmaceuticals and Abraxis BioScience, he not only revolutionized the field but also amassed the wealth necessary to fund his future endeavors.
With NantWorks and its various subsidiaries, Soon-Shiong has set out to transform global healthcare by harnessing the power of technology, data, and innovation. His ventures are paving the way for personalized medicine, improved patient outcomes, and a more efficient healthcare system. Despite facing challenges and controversies—whether in the boardrooms of legacy media institutions or in the competitive world of biotech—his commitment to making a difference remains unwavering.
Beyond his professional success, Soon-Shiong’s dedication to philanthropy and his efforts to support research and education reveal a man who is not only driven by financial success but also by a deep-seated desire to give back to society. His work, whether in improving cancer care or funding vaccine manufacturing in Africa, ensures that his legacy will be measured not just in billions of dollars, but in the lasting impact on global health and the lives of millions.
In the end, Patrick Soon-Shiong stands as a true titan of healthcare—an individual who has leveraged his medical expertise, entrepreneurial spirit, and visionary outlook to reshape the landscape of medicine. His story inspires countless aspiring doctors, researchers, and entrepreneurs, proving that with passion, perseverance, and a willingness to innovate, one can change the world.
Whether you’re a student, a healthcare professional, or simply someone fascinated by the intersection of medicine and business, the life of Patrick Soon-Shiong offers a rich tapestry of lessons in courage, innovation, and the relentless pursuit of excellence.